Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02498613
Title A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Recruitment Active, not recruiting
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

lung small cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

pancreatic adenocarcinoma


Cediranib + Olaparib

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.